Transdermal Drug Delivery Systems Market Size

Global Transdermal Drug Delivery Systems Market Overview

The transdermal drug delivery systems market size was valued at USD 31.9 billion in 2022 and is projected to grow from USD 33.53 billion in 2023 to USD 52.34 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.3% during the forecast period (2023 - 2032). The increasing prevalence of chronic diseases, where conventional drug delivery system, such as oral drugs, has lower potency due to the hepatic first-pass metabolism, is the key market driver expanding the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Market expansion is being driven by the rising incidence of chronic illnesses, which limits the efficacy of traditional drug delivery systems such oral medicines due to their first-pass metabolism in the liver. The need for drugs aimed at the elderly has increased dramatically as the population has grown. Heart disease, diabetes, and arthritis are just a few examples of the chronic illnesses whose patient populations have grown rapidly in recent years. Diseases that last a long time are the leading cause of mortality and disability. Because of these causes, there has been more research and development into improving the efficacy of medications. Additionally, patient education on the appropriate use of certain medications has improved. The global compound annual growth rate of the market for transdermal medication delivery systems has been boosted by these reasons in recent years.

The development of new medications and biologics based on a deeper understanding of the molecular impacts of human illnesses is also made possible by the progress made in a number of biology-focused efforts. Better lipid distribution in the body, resistance to drug degradation from the outside world, and a slower rate of clearance are all benefits of the recently found enhanced transdermal drug delivery methods such lipid, protein, and polymer technologies. Newer pharmaceuticals and biologics require lower doses to achieve the same level of effectiveness. Therefore, they require cutting-edge transdermal medication delivery devices for optimum effectiveness.

January 2024: Kindeva Drug Delivery, a worldwide supplier of drug device combination products, has enhanced its analytical services capabilities by introducing a new global business unit that provides comprehensive and independent analytical support to the broader pharmaceutical, biopharmaceutical, and medical device industry. Kindeva has accumulated extensive knowledge, experience, and competence over a span of more than fifty years in the development of drug delivery programs for inhalation, injection, and transdermal administration, as well as in the provision of commercial supply adhering to current Good Manufacturing Practices (cGMP). In addition, Kindeva has developed extensive knowledge and competence in providing cGMP analytical services to help its partners in product development and supply. Kindeva's newly established laboratories in Woodbury, MN, spanning 32,000 square feet, will not only enhance Kindeva's global analytical presence but also function as the main center for its extended range of independent analytical services.

April 2023: Aveva Drug Delivery Services Inc., a researcher and manufacturer of transdermal delivery systems (TDS) and oral dissolvable films (ODF), was purchased by DifGen Pharmaceuticals LLC (DifGen) in April 2023. With the purchase of Aveva Drug Delivery Services and its 300-plus workers, DifGen has established its first pharmaceutical production facility in the United States, marking a significant milestone for the company. We are able to provide our key partners with a more reliable supply of complicated dosage forms thanks to this well-considered investment in domestic production here in the United States.

Transdermal Drug Delivery Systems Market Trends

• Growing Prevalence of spine degeneration to boost the market growth

The rise in the population has significantly enhanced the demand for geriatric medicines. Transdermal drug delivery systems assist in transdermal drug delivery systems in a controlled manner, thereby Moreover, the number of patients suffering from chronic diseases, including heart disease, diabetes, and arthritis, has significantly enhanced in the past few years. Such chronic diseases are the foremost reason for disability and death ly. These factors have increased R&D activities aimed at enhancing medicines' effectiveness. In addition, awareness among patients regarding the use of various medicines has also been enhanced. These factors have positively impacted the transdermal drug delivery systems market CAGR across the globe in recent years.

Further, advancements in several biology-oriented initiatives have created a unique opportunity to understand the molecular effects of human diseases better and develop novel drugs and biologics based on these factors. The recently discovered advanced transdermal drug delivery systems include lipid, protein, and polymer technologies with better lipid distribution in the body, preventing drug degradation due to the external environment and reducing the rate of drug clearance. Advanced drugs and biologics have higher efficiency with a smaller dosage of drugs. Hence, they must be supported with advanced transdermal drug delivery systems to gain maximum efficacy.

Additionally, drug-eluting implants have the potential to provide uninterrupted treatment and a reduction in drug dosage (hence a less frequent need for dosing). The advanced sustained release systems help target intestinal infections and others. The trend toward self-injection devices and the rapidly growing pipeline of biologics/biosimilars and auto-injectors have also recently emerged as an important class of medical devices. Many companies are focusing on the launch of new products that will contribute to market growth. For instance, in February 2022, Nu Gen Medical Devices Inc. delivered a purchase order from a Taiwanese medical distributor, Shin-Ya Biotechnology Co., Ltd., for its InsuJet needleless injection system. This is part of a multi-year sales and distribution agreement with a minimum commitment of CDN 100,000 over the first two years, with future commitments for the remaining three years of the agreement to be finalized in due course. Such agreements also contribute to the growth of the transdermal drug delivery systems market revenue.

Transdermal Drug Delivery Systems Market Segment Insights

Transdermal Drug Delivery Systems Product Insights

The market segments of transdermal drug delivery systems, based on product, includes transdermal patches and semisolids. The transdermal patches segment held the majority share in 2022 in the transdermal drug delivery systems market revenue. This is primarily due to the emergence of technological innovations, such as the inclusion of microneedles or mechanical arrays in transdermal patches. However, semisolids is the fastest-growing category over the forecast period due to the growing emphasis on implementing inorganic strategies to elevate manufacturing capacity.

Transdermal Drug Delivery Systems Technology Insights

The transdermal drug delivery systems market data has been bifurcated by technology into electric current, iontophoresis, electroporation, ultrasound, and microporation. The iontophoresis segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030 owing to technological advancements. It promotes the movement of ions across the membrane under the influence of a small externally applied potential difference, which has been proven to enhance skin penetration and increase the release rate of several transdermal drug delivery systems with poor absorption/permeation profiles. However, microporation is the fastest-growing category over the forecast period due to an increasing number of product launches by prominent industry players and the numerous microneedle or mechanical array transdermal drug delivery systems products in the late phases of clinical trials exemplify the high market growth for transdermal drug delivery systems.

Figure 1 Transdermal Drug Delivery Systems Market, by Technology, 2022 & 2030 (USD billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

August 2023: The wearable injection device division of Sorrel was acquired by Lohmann Therapie-Systeme (LTS) in August 2023. LTS's increasing portfolio of drug delivery systems will benefit from the addition of a big molecule drug delivery platform made possible by the purchase. Eitan Medical's Sorrel division in Israel creates wearable devices with built-in doses of large-molecule pharmaceuticals for subcutaneous administration. Systems with a pre-filled cartridge and vial are included, as well as those with an internal drug reservoir that is filled at the point of treatment. By purchasing the Sorrel platform, LTS is now able to provide patients who rely on inconvenient and costly medicines that need in-clinic administration or numerous injections access to life-changing alternatives.

April 2023: MIT scientists will unveil a novel transdermal medicine delivery patch designed to overcome the challenges of the current system. The MIT group finds skin to be a promising medication delivery medium. Benefits in wound treatment, pain reduction, and other areas are realized because the medications may be delivered directly to the affected area. The patch works by generating microscopic channels via which medications may be absorbed. The team believes that this strategy might be used to offer therapies for a wide range of skin problems. In addition, they think they can modify it to distribute medications like hormones and muscle relaxants.

Transdermal Drug Delivery Systems Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America transdermal drug delivery systems market accounted for USD 14.61 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the patent expirations, resulting in more companies entering the market across the region. In addition, the repositioning of previously failed drugs, reformulation of existing transdermal drug delivery systems compounds, and huge investments undertaken by prominent and new market entrants are also presumed to be the key factors responsible for the substantial share captured by this region.

Further, the major countries studied in the market report are The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET SHARE BY REGION 2022 (%)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe transdermal drug delivery systems market accounts for the second-largest market share over the forecast period. Well-developed healthcare structure that covers the citizens' healthcare costs promotes more people opting for treatment in the region. Further, the Germany market of transdermal drug delivery systems held the largest market share, and the UK market of transdermal drug delivery systems was the fastest-growing market in the European region.

The Asia-Pacific transdermal drug delivery systems Market is expected to grow at the fastest CAGR from 2022 to 2030. This is due to the growing healthcare spending and the rapidly evolving healthcare infrastructure. Moreover, China market of transdermal drug delivery systems held the largest market share, and the India market of transdermal drug delivery systems was the fastest growing market in the Asia-Pacific region.

Transdermal Drug Delivery Systems Key Market Players & Competitive Insights

Key players are investing a lot of money in R&D to enhance their product lines, which will help the market of transdermal drug delivery systems grow even more. Market participants are also taking several strategic initiatives to expand their worldwide footprint, with key market developments such as new product launches, mergers and acquisitions, increased investments, contractual agreements, and collaboration with other organizations. Competitors in the transdermal drug delivery systems industry must provide cost-effective items to enhance and survive in an increasingly competitive and growing market environment.

One of the major business strategies manufacturers adopt in the transdermal drug delivery systems industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. In the transdermal drug delivery systems market, major players such as Mylan N.V., Hisamitsu Pharmaceutical Co. Inc., Novartis International AG, and others are working on enhancing the market demand by investing in research and development activities.

Corium International, Inc. operates as a biopharmaceutical company. The Company focuses on researching, developing, manufacturing, and commercializing specialty pharmaceutical products for chronic and cancer-related pain. Corium International serves customers worldwide. In March 2022, Corium, Inc. received United States Food and Drug Administration (FDA) approval for Corium's ADLARITY (donepezil transdermal drug delivery systems) treatment for mild, moderate, or severe dementia of Alzheimer's type. ADLARITY is one of the first and only once-weekly patches to deliver consistent doses of donepezil through the skin continuously.

Also, Biomind Labs Inc. operates as a biotech research and development company. The Company focuses on developing novel transdermal drug delivery systems therapies for certain neuropsychiatric and neurodegenerative diseases. Biomind Labs serves customers in Canada. In September 2022, Biomind Labs and Queen's University of Belfast received a controlled substances license to commence the production of a novel transdermal drug delivery systems.

Key Companies in the market of transdermal drug delivery systems include

• Mylan NV.


• Hisamitsu Pharmaceutical Co., Inc.


• Novartis International AG


• Boehringer Ingelheim International GmbH


• GlaxoSmithKline PLC


• Johnson & Johnson Services, Inc.


• Endo Pharmaceuticals Inc.


• UCB SA.


• Pfizer Inc.


• Allergan plc


• Actelion Pharmaceuticals Ltd


• Noven Pharmaceuticals Inc., among others

Transdermal Drug Delivery Systems Industry Developments

June 2021 Shilpa Medicare Ltd. launched an oral thin film formulation, a pediatric dose of paracetamol oral thin film, under the brand name Molshil. Shilpa received approval for Molshil oral thin films after sufficiently complying with bioequivalence requirements. Shilpa's Paracetamol oral thin films are patent protected and are the first of their kind in the world.

March 2022 The United States Food and Drug Administration authorized the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the therapy of two common pulmonary health conditions asthma in patients six years of age and older and chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema.

December 2020 Agile Therapeutics, Inc. commercially launched Twirla (levonorgestrel and Ethinyl estradiol) transdermal drug delivery systems, a new non-daily, non-invasive contraceptive patch in the United States.

Transdermal Drug Delivery Systems Market Segmentation

Transdermal Drug Delivery Systems Product Outlook

• Transdermal Patches


• Semisolids

Transdermal Drug Delivery Systems Technology Outlook

• Electric Current


• Iontophoresis


• Electroporation


• Ultrasound


• Microporation

Transdermal Drug Delivery Systems Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America